Plasmapheresis & Immunosuppressive Drug Therapy in Myasthenia Gravis
NEJM 297:1134, Dau,P.C.,et al, 1977
Penicillamine-associated Myasthenia Gravis, Antiacetylcholine Receptor & Antistriational Antibodies
Am J Med 63:689, Masters,C.L.,et al, 1977
Anti-Acetylcholine Receptor Antibody in Neonatal Myasthenia Gravis
NEJM 296:55, Keesey,J.,et al, 1977
Anti-Acetylcholine Receptor IgG in Neonatal Masthenia Gravis
NEJM 297:169, Nakao,K., 1977
Myasthenia Gravis, Study of Humoral Immune Mechanisms by Passive Transfer to Mice
NEJM 296:125, Toyka,K.V.,et al, 1977
Cause of Weakness in Myasthenia Gravis
NEJM 294:722, Grob,D., 1976
A 68-Year-Old Man with Proximal Weakness and Seizures
Neurol 97:e423-e428, Chen, T., 2021
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Paraneoplastic Neurologic Disorders in Small Cell Lung Carcinoma
Neurol 85:235-239, Gozzard, P.,et al, 2015
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Paraneoplastic Syndromes Involving the Nervous System
NEJM 349:1543-1554, Darnell,R.B. &Posner,J.B., 2003
Paraneoplastic Syndromes
Arch Neurol 56:405-408, Dalmau,J.O.&Posner,J.B., 1999
The Remote Effects of Cancer on the Nervous System
in Neurol Manif of Systemic Dis, W. B. Saunders, Co, Phila, Neurologic Clinics 7:579-603, Dropcho,E.J., 1989
Muscarinic Acetylcholine Receptors in Alzheimer's Disease
JAMA 254:3063-3066, Holman,B.L.,et al, 1985
Ultrastructural Localization of Ach Receptor at the Motor Endplate:MG & Other Neuromuscular Dis
Neurol 30:1203-1211, Tsujihata,M.,et al, 1980
Acetylcholine Receptor in Myasthenia Gravis:Increased Affinity for a-Bungarotoxin
Ann Neurol 4:250-252, Elias,S.B.,et al, 1978
Acetylcholine Receptor Antibodies in Myasthenia Gravis
NEJM 293:760, Appel,S.H.,et al, 1975
Neuromuscular Junction in Myasthenia Gravis:Decreased Acetylcholine Receptors
Science 182:293, Fambrough,D.M.,et al, 1973
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Diagnosis of Lambert-Eaton Myasthenic Syndrome in Children
Neurol 80:e220-e222, Morgan-Followell,B.& de los Reyes,E., 2013
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol 66:1334-1338, 1322, Suzuki,S.,et al, 2009
Ganglionic Acetylcholine Receptor Autoantibody: Oncological, Neurological, and Serological Accompaniments
Arch Neurol 66:735-741, McKeon,A.,et al, 2009
SOX1 Antibodies Are Markers of Paraneoplastic Lambert-Eaton Myasthenic Syndrome
Neurol 70:924-928, Sabater,L.,et al, 2008
Classification of Myasthenia Gravis Based on Autoantibody Status
Arch Neurol 64:1121-1124, Suzuki,S.,et al, 2007
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Antiphospholipid Syndrome and Multiple Ischemic Strokes in a Patient with Myasthenia Gravis
Kurume Med J 49:211-216, Kaji, M.,et al, 2002
Seronegative Lambert-Eaton Myasthenic Syndrome
Neurol 59:1773-1775, Nakao,Y.K.,et al, 2002
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Calcium Channels in Neurological Disease
Ann Neurol 42:275-282, Greenberg,D.A., 1997
Calcium-Channel Antibodies in the Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes
NEJM 332:1467-1474, Lennon,V.A.,et al, 1995
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Clinicopath Conf
Small Cell CA (of lung) with Lambert-Eaton Myasthenic Syndr, Case 32-1994, NEJM 331:528-5354., , 1994
Reversal of Subacute Paraneoplastic Cerebellar Syndrome with Intravenous Immunoglobulin
Neurol 44:1184-1185, Counsell,C.E.,et al, 1994
Paraneoplastic Cerebellar Degener III, Cerebellar Degener, Cancer & Lambert-Eaton Myasthenic Synd
Neurol 42:1944-1950, Clouston,P.D.,et al, 1992